Genome analysis of 11,555 individuals revealed 60 genes involved in congenital heart disease, according to a study published today in the journal PNAS. Congenital heart disease is one of the most common birth defects and affects between 1 and 1.8% of live births.
In the context of World AIDS Day, which is celebrated on 1 December, it is essential to reflect on one of the most urgent challenges in the fight against this disease: HIV in the paediatric population. A project led by the Complutense University of Madrid seeks to reduce paediatric mortality by training research leaders in sub-Saharan Africa and applying technology and innovation.
The relative risk of being born with a major heart defect is 36% in babies conceived using assisted reproductive techniques, such as in vitro fertilisation, compared to newborns not using these techniques, according to a study published in the European Heart Journal. The absolute risk was 1.84% versus 1.15%. The research, which included more than seven million babies born in Denmark, Finland, Norway and Sweden, also shows that the increased risk is especially associated with multiple births, which are more common in assisted reproduction.
A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.
A case-control study published in JAMA Pediatrics reports a relationship between certain aberrant metabolic biomarkers at birth and sudden infant death syndrome (SIDS). Although the research is preliminary and no screening test for this syndrome is yet available, the researchers believe their study is an important step toward integrating metabolic and genetic markers to identify infants at higher risk of sudden death.
Children born in October are more likely to be vaccinated against flu during that month and less likely to be diagnosed with the disease than those born in other months, according to a study published in BMJ. The research involved more than 800,000 US children aged two to five years who were vaccinated against the flu between 1 August and 31 January in the period from 2011 to 2018. The results suggest that the month of birth is related to both the timing of flu vaccination and the likelihood of flu diagnosis, and that October is the best month for flu vaccination.
Since mid-October, northern China has reported an increase in influenza-like illness compared to the same period in the previous three years. On 21 November, the media and the ProMED system reported outbreaks of pneumonia of undiagnosed cause in children in northern China. According to the World Health Organization (WHO), it is unclear whether these are related to the overall increase in respiratory infections previously reported by the Chinese authorities or are separate episodes. In a statement, the WHO has officially requested detailed information from China on this increase in respiratory illnesses and outbreaks of childhood pneumonia.
A study conducted with nearly 58,000 boys and girls revealed that increased television or DVD screen time starting from 12 months of age had a negative impact on later development, as reported by JAMA Pediatrics.
On 5 April, the UK National IHR Focal Point informed WHO of an increase in severe myocarditis in neonates associated with enterovirus infection in Wales (UK). Between June 2022 and April 2023, ten hospitalised neonates with a positive PCR for enterovirus were found to have myocarditis. Seven of the ten cases were confirmed to have coxsackievirus B3 or coxsackievirus B4. As of 5 May 2023, one patient remained hospitalised and one patient had died. According to the WHO statement, although enterovirus infections are common in neonates and infants, the reported increase in myocarditis - inflammation of heart muscle tissue - with severe outcome associated with enterovirus infection is unusual.
A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).